Navigation Links
Adeona Appoints Julie A. Caudill, B.B.A., Vice President of Finance and Corporate Controller
Date:7/27/2010

is a pharmaceutical company developing new medicines for serious central nervous systems diseases. Adeona's primary strategy is to in-license clinical-stage drug candidates that have already demonstrated a certain level of clinical efficacy and develop them to an inflection point in valuation resulting in a significant development and marketing collaboration.  Further information on the company is available at www.adeonapharma.com

This release includes forward-looking statements on Adeona's current expectations and projections about future events. In some cases forward-looking statements can be identified by terminology such as "may," "should," "potential," "continue," "expects," "anticipates," "intends," "plans," "believes," "estimates," and similar expressions. These statements are based upon current beliefs, expectations and assumptions and are subject to a number of risks and uncertainties, many of which are difficult to predict and include statements regarding our growing clinical reference laboratory business. The forward-looking statements are subject to risks and uncertainties that could cause actual results to differ materially from those set forth or implied by any forward-looking statements. Important factors that could cause actual results to differ materially from those reflected in Adeona's forward-looking statements include, among others, a failure of our clinical  trials to achieve desired results, a failure of our clinical reference laboratory to continue to grow or a failure to successfully commercialize products and other factors described in Adeona's report on Form 10-K for the year ended December 31, 2009 and any other filings with the SEC. The information
'/>"/>

SOURCE Adeona Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Anthera Pharmaceuticals Completes $19 Million Financing; Appoints Christopher S. Henney as Chairman
2. Omeros Appoints David A. Mann to its Board of Directors
3. RainDance Technologies Appoints Olex Vice President, System Development
4. ARCA biopharma Appoints William R. Hiatt as Director of Clinical and Regulatory Strategy
5. WuXi AppTec Appoints Garry Takle, Ph.D. as VP of Operations and Joseph Hughes, Ph.D. as VP of Testing Services for Philadelphia Facility
6. Medizone International, Inc. Appoints Dr. Michael E. Shannon to Its Board of Directors
7. US Oncology Appoints Stephen Smith Vice President/General Manager Research and Personalized Science Services
8. RHEI Pharmaceuticals Appoints Dr. Geert Cauwenbergh as Chief Executive Officer
9. UltraShape Appoints Assaf Eyal as President & CEO
10. Regenerative Medicine Appoints Cell Therapy Group Consultant to Editorial Board
11. ThromboGenics Appoints Dr. Patrik De Haes as Chief Executive Officer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/21/2015)... 21, 2015 Progyny, Inc., the new ... announced that it has secured additional capital from investors ... SR One and Merck Serono Ventures. The funding will ... the best fertility outcomes by aligning science, technology, clinics ... marketplace for families seeking fertility solutions and we are ...
(Date:4/21/2015)... YourEncore, an Indianapolis, Indiana-based company that ... and food sciences industries solve complex development, regulatory ... Research Excellence and Safety (ACRES), a Massachusetts-based non-profit ... have partnered to speed innovation in the medical ... to ACRES experts with proven experience, tools, and ...
(Date:4/20/2015)... Texas , April 20, 2015 ... surgeons for healing bone injuries. The orthobiologics market is ... opportunities for its stakeholders. The global orthobiologics market report ... forecast of revenue. The global orthobiologics market was valued ... reach $7,900.2 million by 2019, at a CAGR of ...
(Date:4/20/2015)... 2015  "Everybody is affected by cancer sooner or ... frankly brutal. We,ve got to get away from that."  ... witnessed a loved one or friend battling for their ... chemotherapy and other treatments cause the human body. It,s ... up and succumb to the disease. Dr. Dionne has ...
Breaking Biology Technology:Announcing Progyny: Combining Best-in-Class Clinical Solutions with Consumer Expertise 2YourEncore and ACRES Partner to Drive Innovation in Clinical Research 2YourEncore and ACRES Partner to Drive Innovation in Clinical Research 3Global Orthobiologics Market is Expected to Reach $7,900.2 Million by 2019, at a CAGR of 6.7% from 2014 to 2019 2Global Orthobiologics Market is Expected to Reach $7,900.2 Million by 2019, at a CAGR of 6.7% from 2014 to 2019 3Is Dr. Craig Dionne the Steve Jobs of Cancer Research? 2
... Soyfoods Even HealthierST. LOUIS, March 31 Recent research ... to be beneficial to the diet. And, the majority ... products such as soyfoods even healthier. These findings come ... Survey - sponsored by the United Soybean Board ...
... 30 BioSpecifics Technologies Corp. (Nasdaq: BSTC ... products, today announced its financial results for the fourth ... are very happy to report that our partner Auxilium ... enrollment in a Phase IIb trial in Peyronie,s disease ...
... 30 Mylan Inc. (Nasdaq: MYL ) ... in which it holds a 71.2% controlling interest, has ... and Drug Administration (FDA) under the President,s Emergency Plan ... Application (ANDA) for Emtricitabine and Tenofovir Disoproxil Fumarate Tablets, ...
Cached Biology Technology:Nearly 70 Percent of Health Professionals Support Biotechnology's Use in Food Products 2Nearly 70 Percent of Health Professionals Support Biotechnology's Use in Food Products 3BioSpecifics Technologies Corp. Reports Fourth Quarter and Full Year 2008 Financial Results 2BioSpecifics Technologies Corp. Reports Fourth Quarter and Full Year 2008 Financial Results 3BioSpecifics Technologies Corp. Reports Fourth Quarter and Full Year 2008 Financial Results 4BioSpecifics Technologies Corp. Reports Fourth Quarter and Full Year 2008 Financial Results 5BioSpecifics Technologies Corp. Reports Fourth Quarter and Full Year 2008 Financial Results 6BioSpecifics Technologies Corp. Reports Fourth Quarter and Full Year 2008 Financial Results 7Mylan's Matrix Receives First Tentative FDA Approval Under PEPFAR for Generic Truvada(R) 2
(Date:4/13/2015)... April 13, 2015 According ... "Global Biometrics Market Forecast & Opportunities, 2020", the global ... of around 14% till 2020. The biometrics market ... scale implementation and review of biometric management systems. ... new products with greater efficiency, are resulting in ...
(Date:4/8/2015)... 8, 2015  Infinisource, a leading provider of SaaS-based ... Morpho, a leading supplier of biometric identification and ... market,s most advanced biometrically-enabled time clock, the companies ... clock is setting a bold, new standard for ... the small and mid-size employer. When connected to ...
(Date:4/2/2015)... 2015 According to preliminary estimates ... somewhat higher than 125 MSEK. This exceeds the guidance ... that revenues for Q1 2015 would be in line ... Q4 2014. The operating result for the first quarter ... interim report will as previously communicated be published on ...
Breaking Biology News(10 mins):Global Biometrics Market to Cross US$ 21 Billion by 2020: TechSci Research 2iSolved Time Clock Offers Unmatched Accuracy due to Morpho Biometrics 2iSolved Time Clock Offers Unmatched Accuracy due to Morpho Biometrics 3Fingerprint Cards Revises Revenues for Q1 2015 2
... with a number of pathological conditions, including cancer. Publishing in ... in drinking water given at the maximum levels permitted ... in mice. On the other hand, reducing copper levels reduced ... essential factor for the growth of tumors in humans as ...
... Hall Institute have been awarded more than $2.2 million from ... disorders and inflammatory diseases. Three institute researchers - ... - were announced last week as recipients of ARC Future ... body controls errant immune cells that cause type 1 diabetes ...
... , Nov. 14, 2013  Based on its recent research ... presents Cognitec Systems GmbH with the 2013 European ... Cognitec,s blinkers-on focus on face biometrics earned the ... to develop its flagship face recognition technology, FaceVACS-VideoScan. ...
Cached Biology News:Copper intake makes tumors breathe 2ARC Future Fellows awarded $2.2M for immune and inflammation studies 2Frost & Sullivan Honours Cognitec for Blazing Trails in the Face Biometrics Market with its FaceVACS-VideoScan Technology 2Frost & Sullivan Honours Cognitec for Blazing Trails in the Face Biometrics Market with its FaceVACS-VideoScan Technology 3Frost & Sullivan Honours Cognitec for Blazing Trails in the Face Biometrics Market with its FaceVACS-VideoScan Technology 4Frost & Sullivan Honours Cognitec for Blazing Trails in the Face Biometrics Market with its FaceVACS-VideoScan Technology 5
... I (RNase-free) (E.C. 3.1.21.1) is a nonspecific ... chromatin. It functions by hydrolyzing phosphodiester linkages, ... and a 3'-hydroxyl group. Ambion's RNase-free DNase ... and is recommended to degrade DNA in ...
hnRNP U (H-94)...
... contains a unique β-agarose digesting enzyme developed ... intact DNA and RNA from low melting ... TAE, TBE, MOPS, or phosphate buffers. The ... TAE, TBE, MOPS, and phosphate electrophoresis buffers ...
... is causing shortages in your laboratory or ... cause unwanted distractions, problems and delays. ... your hard work and endeavour! Bring us ... up,and market it internationally. We work under ...
Biology Products: